Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients
Open Access
- 9 July 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1433918
Abstract
Introduction: The aim of this study is to investigate the clinical validity of donor-derived cell-free DNA (dd-cfDNA) in comparison with that of donor specific anti-HLA antibody (DSA) for predicting biopsy-proven rejection (BPR)and severe microvascular inflammation (severe MVI) in kidney transplant recipients (KTRs).Methods: In this prospective observational investigation, 64 KTRs who underwent the indicated biopsies were included. Blood samples collected prior to biopsy were tested for dd-cfDNA and DSA. Biopsy specimens were classified by a renal pathologist according to the Banff classification. The predictive performance of dd-cfDNA and DSA for histological allograft diagnosis was assessed.Results: KTRs were categorized into the high and low dd-cfDNA groups based on a level of 0.4%. Eighteen patients (28.1%) had positive DSA at biopsy, exhibiting higher dd-cfDNA levels than the DSA-negative patients. BPR and severe MVI incidences were elevated in the high dd-cfDNA group (BPR: 42.9% vs. 3.4%, P 0.4%) yielded sensitivities of 80.0% and 50.0% with specificities of 90.7% and 88.0% for antibody-mediated rejection and severe MVI detection, respectively.Conclusion: The dd-cfDNA test is a predictive tool for BPR and severe MVI, and it can improve the performance, especially when combined with DSA for BPR.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2020R1A2B5B01001859)
This publication has 35 references indexed in Scilit:
- Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trialsExpert Opinion on Emerging Drugs, 2022
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Donor-derived cell-free DNA: An independent biomarker in kidney transplant patients with antibody-mediated rejectionTransplant Immunology, 2021
- Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injuryNature Reviews Nephrology, 2021
- The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantationNephrology Dialysis Transplantation, 2019
- A 2018 Reference Guide to the Banff Classification of Renal Allograft PathologyTransplantation, 2018
- Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunctionAmerican Journal of Transplantation, 2018
- Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant RecipientsTransplantation Direct, 2018
- Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcomeAmerican Journal of Transplantation, 2018
- Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant RecipientsThe Journal of Molecular Diagnostics, 2016